English
简体中文
Total: £ 56.28
Published Date: 2025-11-05 | Pages: 158 | Tables: 148 | Medical Care
The global Anti-Rheumatic Drugs market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
Anti-rheumatic drugs are medications used to treat rheumatic diseases, which are conditions characterized by inflammation, pain, stiffness, and swelling in the joints, muscles, and other connective tissues. Rheumatic diseases encompass a wide range of conditions, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, systemic lupus erythematosus (SLE), and juvenile idiopathic arthritis, among others. The goals of treatment with anti-rheumatic drugs are to reduce inflammation, alleviate symptoms, prevent disease progression, and improve overall quality of life for patients.
From a downstream perspective, Hospital Pharmacies accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Anti-Rheumatic Drugs leading manufacturers including Novartis, UCB, AbbVie, Bristol-Myers Squibb, Merck, HEYL Chemisch-pharmazeutische Fabrik, Roche, Johnson & Johnson, Amgen, Pfizer, etc., dominate supply; the top five capture approximately % of global revenue, with Novartis leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Anti-Rheumatic Drugs market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Novartis
UCB
AbbVie
Bristol-Myers Squibb
Merck
HEYL Chemisch-pharmazeutische Fabrik
Roche
Johnson & Johnson
Amgen
Pfizer
GSK
Sanofi
Abbott Laboratories
Teva Pharmaceutical
Eli Lilly and Company
Celltrion
Astellas Pharma
Simcere
Daiichi Sankyo
Asahi Kasei
Segment by Type
Disease Modifying Anti-rheumatics Drugs (DMARD's)
Nonsteroidal Anti-inflammatory Drugs (NSAID's)
Corticosteroids
Uric Acid Drugs
Others
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Sales by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Anti-Rheumatic Drugs study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Study Coverage
1.1 Introduction to Anti-Rheumatic Drugs: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Anti-Rheumatic Drugs Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Disease Modifying Anti-rheumatics Drugs (DMARD's)
1.2.3 Nonsteroidal Anti-inflammatory Drugs (NSAID's)
1.2.4 Corticosteroids
1.2.5 Uric Acid Drugs
1.2.6 Others
1.3 Market Segmentation by Application
1.3.1 Global Anti-Rheumatic Drugs Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Anti-Rheumatic Drugs Revenue Estimates and Forecasts 2020-2031
2.2 Global Anti-Rheumatic Drugs Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Anti-Rheumatic Drugs Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Anti-Rheumatic Drugs Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Disease Modifying Anti-rheumatics Drugs (DMARD's) Market Size by Players
3.3.2 Nonsteroidal Anti-inflammatory Drugs (NSAID's) Market Size by Players
3.3.3 Corticosteroids Market Size by Players
3.3.4 Uric Acid Drugs Market Size by Players
3.3.5 Others Market Size by Players
3.4 Global Anti-Rheumatic Drugs Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Anti-Rheumatic Drugs Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Anti-Rheumatic Drugs Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Anti-Rheumatic Drugs Market Size by Type (2020-2031)
6.4 North America Anti-Rheumatic Drugs Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Anti-Rheumatic Drugs Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Anti-Rheumatic Drugs Market Size by Type (2020-2031)
7.4 Europe Anti-Rheumatic Drugs Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Anti-Rheumatic Drugs Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Anti-Rheumatic Drugs Market Size by Type (2020-2031)
8.4 Asia-Pacific Anti-Rheumatic Drugs Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Anti-Rheumatic Drugs Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Anti-Rheumatic Drugs Market Size by Type (2020-2031)
9.4 Central and South America Anti-Rheumatic Drugs Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Anti-Rheumatic Drugs Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Anti-Rheumatic Drugs Market Size by Type (2020-2031)
10.4 Middle East and Africa Anti-Rheumatic Drugs Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Anti-Rheumatic Drugs Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Novartis
11.1.1 Novartis Corporation Information
11.1.2 Novartis Business Overview
11.1.3 Novartis Anti-Rheumatic Drugs Product Features and Attributes
11.1.4 Novartis Anti-Rheumatic Drugs Revenue and Gross Margin (2020-2025)
11.1.5 Novartis Anti-Rheumatic Drugs Revenue by Product in 2024
11.1.6 Novartis Anti-Rheumatic Drugs Revenue by Application in 2024
11.1.7 Novartis Anti-Rheumatic Drugs Revenue by Geographic Area in 2024
11.1.8 Novartis Anti-Rheumatic Drugs SWOT Analysis
11.1.9 Novartis Recent Developments
11.2 UCB
11.2.1 UCB Corporation Information
11.2.2 UCB Business Overview
11.2.3 UCB Anti-Rheumatic Drugs Product Features and Attributes
11.2.4 UCB Anti-Rheumatic Drugs Revenue and Gross Margin (2020-2025)
11.2.5 UCB Anti-Rheumatic Drugs Revenue by Product in 2024
11.2.6 UCB Anti-Rheumatic Drugs Revenue by Application in 2024
11.2.7 UCB Anti-Rheumatic Drugs Revenue by Geographic Area in 2024
11.2.8 UCB Anti-Rheumatic Drugs SWOT Analysis
11.2.9 UCB Recent Developments
11.3 AbbVie
11.3.1 AbbVie Corporation Information
11.3.2 AbbVie Business Overview
11.3.3 AbbVie Anti-Rheumatic Drugs Product Features and Attributes
11.3.4 AbbVie Anti-Rheumatic Drugs Revenue and Gross Margin (2020-2025)
11.3.5 AbbVie Anti-Rheumatic Drugs Revenue by Product in 2024
11.3.6 AbbVie Anti-Rheumatic Drugs Revenue by Application in 2024
11.3.7 AbbVie Anti-Rheumatic Drugs Revenue by Geographic Area in 2024
11.3.8 AbbVie Anti-Rheumatic Drugs SWOT Analysis
11.3.9 AbbVie Recent Developments
11.4 Bristol-Myers Squibb
11.4.1 Bristol-Myers Squibb Corporation Information
11.4.2 Bristol-Myers Squibb Business Overview
11.4.3 Bristol-Myers Squibb Anti-Rheumatic Drugs Product Features and Attributes
11.4.4 Bristol-Myers Squibb Anti-Rheumatic Drugs Revenue and Gross Margin (2020-2025)
11.4.5 Bristol-Myers Squibb Anti-Rheumatic Drugs Revenue by Product in 2024
11.4.6 Bristol-Myers Squibb Anti-Rheumatic Drugs Revenue by Application in 2024
11.4.7 Bristol-Myers Squibb Anti-Rheumatic Drugs Revenue by Geographic Area in 2024
11.4.8 Bristol-Myers Squibb Anti-Rheumatic Drugs SWOT Analysis
11.4.9 Bristol-Myers Squibb Recent Developments
11.5 Merck
11.5.1 Merck Corporation Information
11.5.2 Merck Business Overview
11.5.3 Merck Anti-Rheumatic Drugs Product Features and Attributes
11.5.4 Merck Anti-Rheumatic Drugs Revenue and Gross Margin (2020-2025)
11.5.5 Merck Anti-Rheumatic Drugs Revenue by Product in 2024
11.5.6 Merck Anti-Rheumatic Drugs Revenue by Application in 2024
11.5.7 Merck Anti-Rheumatic Drugs Revenue by Geographic Area in 2024
11.5.8 Merck Anti-Rheumatic Drugs SWOT Analysis
11.5.9 Merck Recent Developments
11.6 HEYL Chemisch-pharmazeutische Fabrik
11.6.1 HEYL Chemisch-pharmazeutische Fabrik Corporation Information
11.6.2 HEYL Chemisch-pharmazeutische Fabrik Business Overview
11.6.3 HEYL Chemisch-pharmazeutische Fabrik Anti-Rheumatic Drugs Product Features and Attributes
11.6.4 HEYL Chemisch-pharmazeutische Fabrik Anti-Rheumatic Drugs Revenue and Gross Margin (2020-2025)
11.6.5 HEYL Chemisch-pharmazeutische Fabrik Recent Developments
11.7 Roche
11.7.1 Roche Corporation Information
11.7.2 Roche Business Overview
11.7.3 Roche Anti-Rheumatic Drugs Product Features and Attributes
11.7.4 Roche Anti-Rheumatic Drugs Revenue and Gross Margin (2020-2025)
11.7.5 Roche Recent Developments
11.8 Johnson & Johnson
11.8.1 Johnson & Johnson Corporation Information
11.8.2 Johnson & Johnson Business Overview
11.8.3 Johnson & Johnson Anti-Rheumatic Drugs Product Features and Attributes
11.8.4 Johnson & Johnson Anti-Rheumatic Drugs Revenue and Gross Margin (2020-2025)
11.8.5 Johnson & Johnson Recent Developments
11.9 Amgen
11.9.1 Amgen Corporation Information
11.9.2 Amgen Business Overview
11.9.3 Amgen Anti-Rheumatic Drugs Product Features and Attributes
11.9.4 Amgen Anti-Rheumatic Drugs Revenue and Gross Margin (2020-2025)
11.9.5 Amgen Recent Developments
11.10 Pfizer
11.10.1 Pfizer Corporation Information
11.10.2 Pfizer Business Overview
11.10.3 Pfizer Anti-Rheumatic Drugs Product Features and Attributes
11.10.4 Pfizer Anti-Rheumatic Drugs Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
11.11 GSK
11.11.1 GSK Corporation Information
11.11.2 GSK Business Overview
11.11.3 GSK Anti-Rheumatic Drugs Product Features and Attributes
11.11.4 GSK Anti-Rheumatic Drugs Revenue and Gross Margin (2020-2025)
11.11.5 GSK Recent Developments
11.12 Sanofi
11.12.1 Sanofi Corporation Information
11.12.2 Sanofi Business Overview
11.12.3 Sanofi Anti-Rheumatic Drugs Product Features and Attributes
11.12.4 Sanofi Anti-Rheumatic Drugs Revenue and Gross Margin (2020-2025)
11.12.5 Sanofi Recent Developments
11.13 Abbott Laboratories
11.13.1 Abbott Laboratories Corporation Information
11.13.2 Abbott Laboratories Business Overview
11.13.3 Abbott Laboratories Anti-Rheumatic Drugs Product Features and Attributes
11.13.4 Abbott Laboratories Anti-Rheumatic Drugs Revenue and Gross Margin (2020-2025)
11.13.5 Abbott Laboratories Recent Developments
11.14 Teva Pharmaceutical
11.14.1 Teva Pharmaceutical Corporation Information
11.14.2 Teva Pharmaceutical Business Overview
11.14.3 Teva Pharmaceutical Anti-Rheumatic Drugs Product Features and Attributes
11.14.4 Teva Pharmaceutical Anti-Rheumatic Drugs Revenue and Gross Margin (2020-2025)
11.14.5 Teva Pharmaceutical Recent Developments
11.15 Eli Lilly and Company
11.15.1 Eli Lilly and Company Corporation Information
11.15.2 Eli Lilly and Company Business Overview
11.15.3 Eli Lilly and Company Anti-Rheumatic Drugs Product Features and Attributes
11.15.4 Eli Lilly and Company Anti-Rheumatic Drugs Revenue and Gross Margin (2020-2025)
11.15.5 Eli Lilly and Company Recent Developments
11.16 Celltrion
11.16.1 Celltrion Corporation Information
11.16.2 Celltrion Business Overview
11.16.3 Celltrion Anti-Rheumatic Drugs Product Features and Attributes
11.16.4 Celltrion Anti-Rheumatic Drugs Revenue and Gross Margin (2020-2025)
11.16.5 Celltrion Recent Developments
11.17 Astellas Pharma
11.17.1 Astellas Pharma Corporation Information
11.17.2 Astellas Pharma Business Overview
11.17.3 Astellas Pharma Anti-Rheumatic Drugs Product Features and Attributes
11.17.4 Astellas Pharma Anti-Rheumatic Drugs Revenue and Gross Margin (2020-2025)
11.17.5 Astellas Pharma Recent Developments
11.18 Simcere
11.18.1 Simcere Corporation Information
11.18.2 Simcere Business Overview
11.18.3 Simcere Anti-Rheumatic Drugs Product Features and Attributes
11.18.4 Simcere Anti-Rheumatic Drugs Revenue and Gross Margin (2020-2025)
11.18.5 Simcere Recent Developments
11.19 Daiichi Sankyo
11.19.1 Daiichi Sankyo Corporation Information
11.19.2 Daiichi Sankyo Business Overview
11.19.3 Daiichi Sankyo Anti-Rheumatic Drugs Product Features and Attributes
11.19.4 Daiichi Sankyo Anti-Rheumatic Drugs Revenue and Gross Margin (2020-2025)
11.19.5 Daiichi Sankyo Recent Developments
11.20 Asahi Kasei
11.20.1 Asahi Kasei Corporation Information
11.20.2 Asahi Kasei Business Overview
11.20.3 Asahi Kasei Anti-Rheumatic Drugs Product Features and Attributes
11.20.4 Asahi Kasei Anti-Rheumatic Drugs Revenue and Gross Margin (2020-2025)
11.20.5 Asahi Kasei Recent Developments
12 Anti-Rheumatic DrugsIndustry Chain Analysis
12.1 Anti-Rheumatic Drugs Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Anti-Rheumatic Drugs Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Anti-Rheumatic Drugs Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global Anti-Rheumatic Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Anti-Rheumatic Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Anti-Rheumatic Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Anti-Rheumatic Drugs Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Anti-Rheumatic Drugs Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Anti-Rheumatic Drugs Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Anti-Rheumatic Drugs Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Anti-Rheumatic Drugs by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-Rheumatic Drugs as of 2024)
Table 11. Global Anti-Rheumatic Drugs Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Anti-Rheumatic Drugs Companies Headquarters
Table 13. Global Anti-Rheumatic Drugs Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Anti-Rheumatic Drugs Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Anti-Rheumatic Drugs Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Anti-Rheumatic Drugs Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Anti-Rheumatic Drugs Revenue by Application (2026-2031) & (US$ Million)
Table 21. Anti-Rheumatic Drugs High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Anti-Rheumatic Drugs Growth Accelerators and Market Barriers
Table 25. North America Anti-Rheumatic Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Anti-Rheumatic Drugs Growth Accelerators and Market Barriers
Table 27. Europe Anti-Rheumatic Drugs Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Anti-Rheumatic Drugs Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Anti-Rheumatic Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Anti-Rheumatic Drugs Investment Opportunities and Key Challenges
Table 31. Central and South America Anti-Rheumatic Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Anti-Rheumatic Drugs Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Anti-Rheumatic Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. Novartis Corporation Information
Table 35. Novartis Description and Major Businesses
Table 36. Novartis Product Features and Attributes
Table 37. Novartis Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. Novartis Revenue Proportion by Product in 2024
Table 39. Novartis Revenue Proportion by Application in 2024
Table 40. Novartis Revenue Proportion by Geographic Area in 2024
Table 41. Novartis Anti-Rheumatic Drugs SWOT Analysis
Table 42. Novartis Recent Developments
Table 43. UCB Corporation Information
Table 44. UCB Description and Major Businesses
Table 45. UCB Product Features and Attributes
Table 46. UCB Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. UCB Revenue Proportion by Product in 2024
Table 48. UCB Revenue Proportion by Application in 2024
Table 49. UCB Revenue Proportion by Geographic Area in 2024
Table 50. UCB Anti-Rheumatic Drugs SWOT Analysis
Table 51. UCB Recent Developments
Table 52. AbbVie Corporation Information
Table 53. AbbVie Description and Major Businesses
Table 54. AbbVie Product Features and Attributes
Table 55. AbbVie Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. AbbVie Revenue Proportion by Product in 2024
Table 57. AbbVie Revenue Proportion by Application in 2024
Table 58. AbbVie Revenue Proportion by Geographic Area in 2024
Table 59. AbbVie Anti-Rheumatic Drugs SWOT Analysis
Table 60. AbbVie Recent Developments
Table 61. Bristol-Myers Squibb Corporation Information
Table 62. Bristol-Myers Squibb Description and Major Businesses
Table 63. Bristol-Myers Squibb Product Features and Attributes
Table 64. Bristol-Myers Squibb Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. Bristol-Myers Squibb Revenue Proportion by Product in 2024
Table 66. Bristol-Myers Squibb Revenue Proportion by Application in 2024
Table 67. Bristol-Myers Squibb Revenue Proportion by Geographic Area in 2024
Table 68. Bristol-Myers Squibb Anti-Rheumatic Drugs SWOT Analysis
Table 69. Bristol-Myers Squibb Recent Developments
Table 70. Merck Corporation Information
Table 71. Merck Description and Major Businesses
Table 72. Merck Product Features and Attributes
Table 73. Merck Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. Merck Revenue Proportion by Product in 2024
Table 75. Merck Revenue Proportion by Application in 2024
Table 76. Merck Revenue Proportion by Geographic Area in 2024
Table 77. Merck Anti-Rheumatic Drugs SWOT Analysis
Table 78. Merck Recent Developments
Table 79. HEYL Chemisch-pharmazeutische Fabrik Corporation Information
Table 80. HEYL Chemisch-pharmazeutische Fabrik Description and Major Businesses
Table 81. HEYL Chemisch-pharmazeutische Fabrik Product Features and Attributes
Table 82. HEYL Chemisch-pharmazeutische Fabrik Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. HEYL Chemisch-pharmazeutische Fabrik Recent Developments
Table 84. Roche Corporation Information
Table 85. Roche Description and Major Businesses
Table 86. Roche Product Features and Attributes
Table 87. Roche Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. Roche Recent Developments
Table 89. Johnson & Johnson Corporation Information
Table 90. Johnson & Johnson Description and Major Businesses
Table 91. Johnson & Johnson Product Features and Attributes
Table 92. Johnson & Johnson Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. Johnson & Johnson Recent Developments
Table 94. Amgen Corporation Information
Table 95. Amgen Description and Major Businesses
Table 96. Amgen Product Features and Attributes
Table 97. Amgen Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. Amgen Recent Developments
Table 99. Pfizer Corporation Information
Table 100. Pfizer Description and Major Businesses
Table 101. Pfizer Product Features and Attributes
Table 102. Pfizer Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. Pfizer Recent Developments
Table 104. GSK Corporation Information
Table 105. GSK Description and Major Businesses
Table 106. GSK Product Features and Attributes
Table 107. GSK Revenue (US$ Million) and Gross Margin (2020-2025)
Table 108. GSK Recent Developments
Table 109. Sanofi Corporation Information
Table 110. Sanofi Description and Major Businesses
Table 111. Sanofi Product Features and Attributes
Table 112. Sanofi Revenue (US$ Million) and Gross Margin (2020-2025)
Table 113. Sanofi Recent Developments
Table 114. Abbott Laboratories Corporation Information
Table 115. Abbott Laboratories Description and Major Businesses
Table 116. Abbott Laboratories Product Features and Attributes
Table 117. Abbott Laboratories Revenue (US$ Million) and Gross Margin (2020-2025)
Table 118. Abbott Laboratories Recent Developments
Table 119. Teva Pharmaceutical Corporation Information
Table 120. Teva Pharmaceutical Description and Major Businesses
Table 121. Teva Pharmaceutical Product Features and Attributes
Table 122. Teva Pharmaceutical Revenue (US$ Million) and Gross Margin (2020-2025)
Table 123. Teva Pharmaceutical Recent Developments
Table 124. Eli Lilly and Company Corporation Information
Table 125. Eli Lilly and Company Description and Major Businesses
Table 126. Eli Lilly and Company Product Features and Attributes
Table 127. Eli Lilly and Company Revenue (US$ Million) and Gross Margin (2020-2025)
Table 128. Eli Lilly and Company Recent Developments
Table 129. Celltrion Corporation Information
Table 130. Celltrion Description and Major Businesses
Table 131. Celltrion Product Features and Attributes
Table 132. Celltrion Revenue (US$ Million) and Gross Margin (2020-2025)
Table 133. Celltrion Recent Developments
Table 134. Astellas Pharma Corporation Information
Table 135. Astellas Pharma Description and Major Businesses
Table 136. Astellas Pharma Product Features and Attributes
Table 137. Astellas Pharma Revenue (US$ Million) and Gross Margin (2020-2025)
Table 138. Astellas Pharma Recent Developments
Table 139. Simcere Corporation Information
Table 140. Simcere Description and Major Businesses
Table 141. Simcere Product Features and Attributes
Table 142. Simcere Revenue (US$ Million) and Gross Margin (2020-2025)
Table 143. Simcere Recent Developments
Table 144. Daiichi Sankyo Corporation Information
Table 145. Daiichi Sankyo Description and Major Businesses
Table 146. Daiichi Sankyo Product Features and Attributes
Table 147. Daiichi Sankyo Revenue (US$ Million) and Gross Margin (2020-2025)
Table 148. Daiichi Sankyo Recent Developments
Table 149. Asahi Kasei Corporation Information
Table 150. Asahi Kasei Description and Major Businesses
Table 151. Asahi Kasei Product Features and Attributes
Table 152. Asahi Kasei Revenue (US$ Million) and Gross Margin (2020-2025)
Table 153. Asahi Kasei Recent Developments
Table 154. Raw Materials Key Suppliers
Table 155. Distributors List
Table 156. Market Trends and Market Evolution
Table 157. Market Drivers and Opportunities
Table 158. Market Challenges, Risks, and Restraints
Table 159. Research Programs/Design for This Report
Table 160. Key Data Information from Secondary Sources
Table 161. Key Data Information from Primary Sources
List of Figures
Figure 1. Anti-Rheumatic Drugs Product Picture
Figure 2. Global Anti-Rheumatic Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Disease Modifying Anti-rheumatics Drugs (DMARD's) Product Picture
Figure 4. Nonsteroidal Anti-inflammatory Drugs (NSAID's) Product Picture
Figure 5. Corticosteroids Product Picture
Figure 6. Uric Acid Drugs Product Picture
Figure 7. Others Product Picture
Figure 8. Global Anti-Rheumatic Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 9. Hospital Pharmacies
Figure 10. Retail Pharmacies
Figure 11. Online Pharmacies
Figure 12. Anti-Rheumatic Drugs Report Years Considered
Figure 13. Global Anti-Rheumatic Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Anti-Rheumatic Drugs Revenue (2020-2031) & (US$ Million)
Figure 15. Global Anti-Rheumatic Drugs Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 16. Global Anti-Rheumatic Drugs Revenue Market Share by Region (2020-2031)
Figure 17. Global Anti-Rheumatic Drugs Revenue Market Share Ranking (2024)
Figure 18. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 19. Disease Modifying Anti-rheumatics Drugs (DMARD's) Revenue Market Share by Player in 2024
Figure 20. Nonsteroidal Anti-inflammatory Drugs (NSAID's) Revenue Market Share by Player in 2024
Figure 21. Corticosteroids Revenue Market Share by Player in 2024
Figure 22. Uric Acid Drugs Revenue Market Share by Player in 2024
Figure 23. Others Revenue Market Share by Player in 2024
Figure 24. Global Anti-Rheumatic Drugs Revenue Market Share by Type (2020-2031)
Figure 25. Global Anti-Rheumatic Drugs Revenue Market Share by Application (2020-2031)
Figure 26. North America Anti-Rheumatic Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 27. North America Top 5 Players Anti-Rheumatic Drugs Revenue (US$ Million) in 2024
Figure 28. North America Anti-Rheumatic Drugs Revenue (US$ Million) by Type (2020 - 2031)
Figure 29. North America Anti-Rheumatic Drugs Revenue (US$ Million) by Application (2020-2031)
Figure 30. US Anti-Rheumatic Drugs Revenue (2020-2031) & (US$ Million)
Figure 31. Canada Anti-Rheumatic Drugs Revenue (2020-2031) & (US$ Million)
Figure 32. Mexico Anti-Rheumatic Drugs Revenue (2020-2031) & (US$ Million)
Figure 33. Europe Anti-Rheumatic Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 34. Europe Top 5 Players Anti-Rheumatic Drugs Revenue (US$ Million) in 2024
Figure 35. Europe Anti-Rheumatic Drugs Revenue (US$ Million) by Type (2020-2031)
Figure 36. Europe Anti-Rheumatic Drugs Revenue (US$ Million) by Application (2020-2031)
Figure 37. Germany Anti-Rheumatic Drugs Revenue (2020-2031) & (US$ Million)
Figure 38. France Anti-Rheumatic Drugs Revenue (2020-2031) & (US$ Million)
Figure 39. U.K. Anti-Rheumatic Drugs Revenue (2020-2031) & (US$ Million)
Figure 40. Italy Anti-Rheumatic Drugs Revenue (2020-2031) & (US$ Million)
Figure 41. Russia Anti-Rheumatic Drugs Revenue (2020-2031) & (US$ Million)
Figure 42. Asia-Pacific Anti-Rheumatic Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 43. Asia-Pacific Top 8 Players Anti-Rheumatic Drugs Revenue (US$ Million) in 2024
Figure 44. Asia-Pacific Anti-Rheumatic Drugs Revenue (US$ Million) by Type (2020-2031)
Figure 45. Asia-Pacific Anti-Rheumatic Drugs Revenue (US$ Million) by Application (2020-2031)
Figure 46. Indonesia Anti-Rheumatic Drugs Revenue (2020-2031) & (US$ Million)
Figure 47. Japan Anti-Rheumatic Drugs Revenue (2020-2031) & (US$ Million)
Figure 48. South Korea Anti-Rheumatic Drugs Revenue (2020-2031) & (US$ Million)
Figure 49. Australia Anti-Rheumatic Drugs Revenue (2020-2031) & (US$ Million)
Figure 50. India Anti-Rheumatic Drugs Revenue (2020-2031) & (US$ Million)
Figure 51. Indonesia Anti-Rheumatic Drugs Revenue (2020-2031) & (US$ Million)
Figure 52. Vietnam Anti-Rheumatic Drugs Revenue (2020-2031) & (US$ Million)
Figure 53. Malaysia Anti-Rheumatic Drugs Revenue (2020-2031) & (US$ Million)
Figure 54. Philippines Anti-Rheumatic Drugs Revenue (2020-2031) & (US$ Million)
Figure 55. Singapore Anti-Rheumatic Drugs Revenue (2020-2031) & (US$ Million)
Figure 56. Central and South America Anti-Rheumatic Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 57. Central and South America Top 5 Players Anti-Rheumatic Drugs Revenue (US$ Million) in 2024
Figure 58. Central and South America Anti-Rheumatic Drugs Revenue (US$ Million) by Type (2020-2031)
Figure 59. Central and South America Anti-Rheumatic Drugs Revenue (US$ Million) by Application (2020-2031)
Figure 60. Brazil Anti-Rheumatic Drugs Revenue (2020-2025) & (US$ Million)
Figure 61. Argentina Anti-Rheumatic Drugs Revenue (2020-2025) & (US$ Million)
Figure 62. Middle East and Africa Anti-Rheumatic Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 63. Middle East and Africa Top 5 Players Anti-Rheumatic Drugs Revenue (US$ Million) in 2024
Figure 64. South America Anti-Rheumatic Drugs Revenue (US$ Million) by Type (2020-2031)
Figure 65. Middle East and Africa Anti-Rheumatic Drugs Revenue (US$ Million) by Application (2020-2031)
Figure 66. GCC Countries Anti-Rheumatic Drugs Revenue (2020-2025) & (US$ Million)
Figure 67. Israel Anti-Rheumatic Drugs Revenue (2020-2025) & (US$ Million)
Figure 68. Egypt Anti-Rheumatic Drugs Revenue (2020-2025) & (US$ Million)
Figure 69. South Africa Anti-Rheumatic Drugs Revenue (2020-2025) & (US$ Million)
Figure 70. Anti-Rheumatic Drugs Industry Chain Mapping
Figure 71. Channels of Distribution (Direct Vs Distribution)
Figure 72. Bottom-up and Top-down Approaches for This Report
Figure 73. Data Triangulation
Figure 74. Key Executives Interviewed
